बेक्सारोटीन के इंटरैक्शन

Acitretin is contraindicated in cases of hypersensitivity (e.g., angioedema, urticaria) to the preparation (acitretin or excipients) or to other retinoids . (एसिट्रेटिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Because of a potential drug-drug interaction, avoid gemfibrozil use with TARGRETIN [ see Drug Interactions (7) ]. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Concomitant use of isotretinoin and tetracycline should be avoided because isotretinoin, a systemic retinoid, is also known to cause pseudotumor cerebri. (टेट्रासाइक्लिन लेबल, चेतावनियां)

Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (ट्रेटिनोइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Avoid concomitant use of isotretinoin and EMROSI because isotretinoin, a systemic retinoid, is also known to cause idiopathic intracranial hypertension. (मिनोसाइक्लिन लेबल, चेतावनियां और सावधानियां)

Patients with elevated vitamin A levels may be at increased risk. (आइवाकैफ्टर लेबल, चेतावनियां और सावधानियां)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Patients with elevated vitamin A levels may be at increased risk. (एलेक्साकैफ्टर, टेज़ाकैफ्टर और आइवाकैफ्टर लेबल, चेतावनियां और सावधानियां)

The effect of ORLISTAT on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time [see Clinical Pharmacology (12.3) , and Warnings and Precautions (5.1) ] . (ऑर्लिस्टैट लेबल, दवाओं के इंटरैक्शन)

Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (कैल्शियम क्लोराइड लेबल, दवाओं के इंटरैक्शन)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Monitor and replace thyroid hormone if needed. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Monitor and replace thyroid hormone if needed. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Monitor and replace thyroid hormone if needed. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Monitor patients receiving XATMEP with other potential hepatotoxins (e.g., azathioprine, retinoids, and sulfasalazine) for possible signs of hepatotoxicity. (मेथोट्रेक्सेट लेबल, दवाओं के इंटरैक्शन)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Monitor and replace thyroid hormone if needed. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Monitor and replace thyroid hormone if needed. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Monitor and replace thyroid hormone if needed. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Patients with CTCL who have risk factors for pancreatitis (e.g., prior pancreatitis, uncontrolled hyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus, biliary tract disease, and medications known to increase triglyceride levels or to be associated with pancreatic toxicity) may be at greater risk for pancreatitis associated with TARGRETIN… (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Atorvastatin was used in 48% (73/152) of patients with CTCL. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Atorvastatin was used in 48% (73/152) of patients with CTCL. (बेक्सारोटीन लेबल, चेतावनियां और सावधानियां)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (कैल्शियम ग्लूकोनेट लेबल, दवाओं के इंटरैक्शन)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Vitamin A Based on a case report in one patient receiving combination therapy with all-trans-retinoid acid (an acid form of vitamin A) and fluconazole, central nervous system (CNS) related undesirable effects have developed in the form of pseudotumor cerebri, which disappeared after discontinuation of fluconazole treatment. (फ्लुकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)